JP2023536086A - Ｐｄ‐１×ｃｔｌａ‐４二重特異性分子の使用のための方法 - Google Patents

Ｐｄ‐１×ｃｔｌａ‐４二重特異性分子の使用のための方法 Download PDF

Info

Publication number
JP2023536086A
JP2023536086A JP2023505707A JP2023505707A JP2023536086A JP 2023536086 A JP2023536086 A JP 2023536086A JP 2023505707 A JP2023505707 A JP 2023505707A JP 2023505707 A JP2023505707 A JP 2023505707A JP 2023536086 A JP2023536086 A JP 2023536086A
Authority
JP
Japan
Prior art keywords
cancer
ctla
dose
bispecific molecule
1xctla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023505707A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536086A5 (https=
Inventor
ブラッドレイ ジェームズ スムラウ
エツィオ ボンビニ
シャラド シャルマ
ジョン マーク ウィギントン
アレクセイ エフゲニエビッチ ベレジノイ
Original Assignee
マクロジェニクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マクロジェニクス，インコーポレーテッド filed Critical マクロジェニクス，インコーポレーテッド
Publication of JP2023536086A publication Critical patent/JP2023536086A/ja
Publication of JP2023536086A5 publication Critical patent/JP2023536086A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2023505707A 2020-07-27 2021-07-23 Ｐｄ‐１×ｃｔｌａ‐４二重特異性分子の使用のための方法 Pending JP2023536086A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063057054P 2020-07-27 2020-07-27
US63/057,054 2020-07-27
US202163177036P 2021-04-20 2021-04-20
US63/177,036 2021-04-20
US202163219066P 2021-07-07 2021-07-07
US63/219,066 2021-07-07
PCT/US2021/042901 WO2022026306A1 (en) 2020-07-27 2021-07-23 Methods for the use of a pd-1 x ctla-4 bispecific molecule

Publications (2)

Publication Number Publication Date
JP2023536086A true JP2023536086A (ja) 2023-08-23
JP2023536086A5 JP2023536086A5 (https=) 2024-07-29

Family

ID=80036053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023505707A Pending JP2023536086A (ja) 2020-07-27 2021-07-23 Ｐｄ‐１×ｃｔｌａ‐４二重特異性分子の使用のための方法

Country Status (13)

Country Link
US (1) US20230312756A1 (https=)
EP (1) EP4188961A4 (https=)
JP (1) JP2023536086A (https=)
KR (1) KR20230042038A (https=)
CN (1) CN116134053A (https=)
AU (1) AU2021316192A1 (https=)
BR (1) BR112023001487A2 (https=)
CA (1) CA3189926A1 (https=)
IL (1) IL300166A (https=)
MX (1) MX2023001111A (https=)
TW (1) TW202220691A (https=)
WO (1) WO2022026306A1 (https=)
ZA (1) ZA202300822B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120648657A (zh) * 2024-03-08 2025-09-16 上海锦斯生物技术有限公司 一种修饰的溶瘤病毒及其组合物
WO2026021409A1 (zh) * 2024-07-22 2026-01-29 宜明昂科生物医药技术（上海）股份有限公司 靶向ctla-4、pd-l1和vegf的肿瘤联合疗法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019506444A (ja) * 2015-12-14 2019-03-07 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
JP2019520797A (ja) * 2016-05-06 2019-07-25 メディミューン，エルエルシー 二重特異性結合タンパク質およびその使用
JP2019524693A (ja) * 2016-07-20 2019-09-05 ナンジン レジェンド バイオテック カンパニー，リミテッドＮａｎｊｉｎｇ Ｌｅｇｅｎｄ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 多重特異性抗原結合タンパク質及びその使用方法
JP2019525738A (ja) * 2016-06-14 2019-09-12 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体
JP2019533475A (ja) * 2016-08-23 2019-11-21 康方▲藥▼▲業▼有限公司Ａｋｅｓｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｃｔｌａ４−抗ｐｄ−１二機能性抗体、その医薬組成物および使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2439273T3 (da) * 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
WO2019179421A1 (en) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/ctla-4 antibody molecules

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019506444A (ja) * 2015-12-14 2019-03-07 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
JP2019520797A (ja) * 2016-05-06 2019-07-25 メディミューン，エルエルシー 二重特異性結合タンパク質およびその使用
JP2019525738A (ja) * 2016-06-14 2019-09-12 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体
JP2019524693A (ja) * 2016-07-20 2019-09-05 ナンジン レジェンド バイオテック カンパニー，リミテッドＮａｎｊｉｎｇ Ｌｅｇｅｎｄ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 多重特異性抗原結合タンパク質及びその使用方法
JP2019533475A (ja) * 2016-08-23 2019-11-21 康方▲藥▼▲業▼有限公司Ａｋｅｓｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｃｔｌａ４−抗ｐｄ−１二機能性抗体、その医薬組成物および使用

Also Published As

Publication number Publication date
IL300166A (en) 2023-03-01
MX2023001111A (es) 2023-03-07
ZA202300822B (en) 2023-08-30
US20230312756A1 (en) 2023-10-05
EP4188961A1 (en) 2023-06-07
KR20230042038A (ko) 2023-03-27
TW202220691A (zh) 2022-06-01
CA3189926A1 (en) 2022-02-03
AU2021316192A1 (en) 2023-02-23
BR112023001487A2 (pt) 2023-02-14
CN116134053A (zh) 2023-05-16
WO2022026306A1 (en) 2022-02-03
EP4188961A4 (en) 2024-08-07

Similar Documents

Publication Publication Date Title
TWI788327B (zh) 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途
JP7746258B2 (ja) 特性が改善されたｐｄ－１標的化ｉｌ－１５／ｉｌ－１５ｒαｆｃ融合タンパク質
CN109641049B (zh) Cd3结合抗体
CN113301919A (zh) 激活免疫细胞的双特异性抗体
TW201811829A (zh) 針對tim3之抗體及其用途
TW201617369A (zh) 能夠結合cd19和cd3的雙特異性單價雙抗體及其用途
TW201627322A (zh) 抗-ｄｒ５抗體和包括其ｄｒ５-結合結構域的分子
US20230056230A1 (en) Therapy for the Treatment of Cancer
TW201627323A (zh) 包含dr5-結合結構域的多價分子
TWI814758B (zh) 雙特異性ｃｄ１６-結合分子及其在疾病治療中的用途
JP2023536086A (ja) Ｐｄ‐１×ｃｔｌａ‐４二重特異性分子の使用のための方法
US20250101104A1 (en) Bispecific molecule with tunable affinity to a targeted antigen
RU2805648C2 (ru) Биспецифические связывающие молекулы, способные связывать cd137 и опухолевые антигены, и варианты их применения
EA046873B1 (ru) Cd137-связывающие молекулы и варианты их применения
HK40113244A (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260310